Kerry Cullinan Health-e News
A leading paediatrician has described the treatment delay as shameful,
while the Treatment Action Campaign (TAC) says it is considering taking the
government to court to force it to expand its programme. At present, national
treatment for the prevention of mother-to-child transmission consists of
administering a dose of Nevirapine to women when they are in labour and a dose
to their babies within 72 hours of birth.
However, a year ago the World Health Organisation recommended that pregnant
HIV- positive women in developing countries should get dual therapy,
comprising Nevirapine and a short course of AZT to protect their babies from HIV
infection. The Western Cape has been using both Nevirapine and AZT since May
2004 and has managed to reduce its mother-to- child HIV infection rate to around
8%. By contrast, in KwaZulu-Natal , with its nevirapine-only regimen, 22% of
HIV-positive mothers are passing on the virus.
In KwaZulu-Natal alone, 20 000 to 30 000 children are being infected with
HIV each year and half of them will need antiretroviral drugs by the age of 12
months, said Professor Nigel Rollins, head of the Centre for Maternal and
Child Health at the University of KwaZulu-Natal . The delay in introducing
dual therapy is shameful. How can women and babies be denied treatment when
people on the ground say it can be implemented? Rollins said. South Africa is
one of only nine countries in the world where the child mortality rate is
increasing instead of dropping mainly as a result of children dying of
Aids-related illnesses. The Medical Research Council, the National Essential
Drugs Committee and the Medicines Control Council have all recommended to the
government that the country adopt dual therapy.
Many doctors working in government hospitals say they were told in December
to prepare themselves for the imminent introduction of dual therapy. But the
National Health Council made up of the health minister, provincial health
MECs and heads of department has consistently failed to make dual therapy
national policy or even to set up a task team to investigate its introduction.
Health spokesman Sibani Mngadi confirmed the council had discussed dual therapy,
but he refused to be drawn on whether the department intended to change its
protocol or when this might happen. The National Strategic Plan, adopted by
Cabinet, has made room for the introduction of dual therapy, said Mngadi.
But when asked if hospitals that were ready could introduce dual therapy, he
said ideally this should not be the case since overarching policies and
guidelines stem from the national Department of Health. Many hospitals in
KwaZulu- Natal and Gauteng are ready to implement dual therapy. The Northern
Cape Health Department has already approved dual therapy but is waiting for the
national governments go-ahead before implementing it. KwaZulu-Natal health
spokesman Leon Mbangwa said that while his province was preparing to introduce
dual therapy, this would not be done until we have received a national
directive to do so as it is not yet national policy to use dual therapy in
South Africa .
Dr Victor Fredlund confirmed he had been corresponding with the national
and provincial departments for the past eight months about the desire of five
hospitals in Umkhanyakude [in the far north of KwaZulu-Natal ] to implement dual
therapy. Fredlunds Mseleni Hospital is offering the therapy to patients
who can afford AZT. Gauteng health spokesman Zanele Mngadi simply said that dual
therapy was under review and it is envisaged that a decision will be
made in this regard soon. A Tshwane doctor who asked not to be named said his
hospital had already started dual therapy as we think it is better to have to
say sorry afterwards than to ask permission. TAC spokesman Nathan Geffen said
his organisation could not understand the delay, as dual therapy will save
the lives of babies and reduce the burden on the health system of caring for
sick children.
Geffen said although it would prefer not to, the TAC was considering court
action to compel the government to introduce dual therapy. In 2003, the TAC
succeeded in getting the courts to compel the government to make Nevirapine
available to pregnant HIV-positive women. This week the Joint Civil Society
Monitoring Forum, which represents more than 20 health and civil society
organisations, wrote to the Health Department and asked it to immediately allow
provinces that were ready to offer dual therapy and to set up a task team to
consider how best to implement the WHO recommendations on dual therapy. Forum
spokesman Fatima Hassan said: There is no good public-health reason to stall
the implementation of dual therapy. It is not difficult to implement. If we are
serious about preventing HIV, we must start by preventing babies from getting
HIV.
In May, Dr Francois Venter, president of the SA HIV Clinicians Society, wrote
to the SA National Aids Council asking it to investigate the delay. Several
doctors and ARV managers in both rural and urban environments have raised the
issue that they have been promised updated guidelines repeatedly, but these have
not been forthcoming, he wrote. The new National HIV/Aids Strategic Plan aims
to reduce the rate of mother-to-child transmission to 5% by 2011. Pregnant women
with high viral loads and low CD4 counts (the measure of immunity in the blood)
are most likely to transmit HIV to their babies, but this risk can be
substantially reduced by treating them with at least two antiretroviral drugs to
make them less infectious. We will never cut the transmission rate to 5% with
one dose of Nevirapine. In the US and Europe , mother-to-child transmission has
been reduced to around 2% with the use of two to three antiretroviral drugs,
said Venter. If we fix mother-to-child HIV transmission, we dont have to
expand child HIV treatment, Venter said.